(Q34517532)

2 August 2017

1 reference

title

Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy (English)

1 reference

2 August 2017

1 reference

Leticia R Villela

1

1 reference

2 August 2017

Brad L Stanford

series ordinal

2

1 reference

2 August 2017

Sachin R Shah

series ordinal

3

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

2 August 2017

1 reference

2 August 2017

volume

26

1 reference

2 August 2017

issue

5

1 reference

2 August 2017

page(s)

641-654

1 reference

Folate status and the safety profile of antifolates

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

FDA drug approval summaries: pemetrexed (Alimta).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Pemetrexed (Alimta®): a novel multitargeted antifolate agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Enter Alimta: a new generation antifolate

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Thymidine Rescue: An Antidote for Pemetrexed-Related Toxicity in the Setting of Acute Renal Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Advances in malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

21 January 2018

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Multidisciplinary management of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

The ALPI Trial: the Italian/European experience with adjuvant chemotherapy in resectable non-small lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Pemetrexed (Alimta) in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

A phase II trial of pemetrexed in patients with metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Overview of combined modality therapies for head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Understanding the cancer biology universe: enigmas, context and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Deterioration in lung function following hemithorax irradiation for pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

Treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5.641

21 January 2018

Identifiers

DOI

10.1592/PHCO.26.5.641

1 reference

2 August 2017

1 reference